Literature DB >> 8306368

Growth inhibition of a colonic adenocarcinoma cell line (HT29) by T cells specific for mutant p21 ras.

T Gedde-Dahl1, E Nilsen, E Thorsby, G Gaudernack.   

Abstract

Mutations at codons 12, 13 or 61 of the ras proto-oncogenes are found in adenocarcinomas of the colon and rectum. Mutated ras encode tumor-specific proteins, and can elicit CD4+ HLA-class-II-restricted T cell responses both in mouse and man. The function of such T cells is, however, unclear. In a model system, we investigated whether HLA-class-II restricted CD4+ T cells, specific for a particular peptide derived from mutant p21 ras (Gln61-->Leu), might inhibit the growth of a colonic cancer cell line, when it was cultured in the presence of the corresponding peptide. We found in this case that the growth of the colonic adenocarcinoma cell line HT29, when also induced to express HLA class II molecules by interferon gamma treatment, was inhibited. The inhibition was peptide-specific and required the presence of HLA-DQ8 molecules on the target cell. However, HLA-DQ8-expressing HT29 cells functioned poorly as antigen-presenting cells and could only induce a weak proliferative T cell response in the presence of interleukin-2. The results suggest that colonic cancer cells expressing peptides derived from mutant p21 ras protein in a complex with HLA class II molecules may be a target for tumor-specific T cells. The results also indicate, however, that an initiation of the immune response will require "professional" antigen-presenting cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8306368

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  40 in total

1.  Rapid immunomagnetic phenotyping of cells.

Authors:  G Gaudernack; K E Lundin
Journal:  J Immunogenet       Date:  1989-04

2.  Idiotope-specific T cell clones that recognize syngeneic immunoglobulin fragments in the context of class II molecules.

Authors:  B Bogen; B Malissen; W Haas
Journal:  Eur J Immunol       Date:  1986-11       Impact factor: 5.532

3.  MHC class II-restricted presentation of intracellular antigen.

Authors:  S Weiss; B Bogen
Journal:  Cell       Date:  1991-02-22       Impact factor: 41.582

4.  Intracellular events associated with inhibition of B cell activation by monoclonal antibodies to HLA class II antigens.

Authors:  H Holte; H K Blomhoff; K Beiske; S Funderud; P Torjesen; G Gaudernack; T Stokke; E B Smeland
Journal:  Eur J Immunol       Date:  1989-07       Impact factor: 5.532

5.  A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes.

Authors:  T Espevik; J Nissen-Meyer
Journal:  J Immunol Methods       Date:  1986-12-04       Impact factor: 2.303

6.  The detailed distribution of HLA-A, B, C antigens in normal human organs.

Authors:  A S Daar; S V Fuggle; J W Fabre; A Ting; P J Morris
Journal:  Transplantation       Date:  1984-09       Impact factor: 4.939

7.  T-cell responses against products of oncogenes: generation and characterization of human T-cell clones specific for p21 ras-derived synthetic peptides.

Authors:  T Gedde-Dahl; J A Eriksen; E Thorsby; G Gaudernack
Journal:  Hum Immunol       Date:  1992-04       Impact factor: 2.850

8.  Expression of two distinct cytolytic mechanisms among murine CD4 subsets.

Authors:  S T Ju; N H Ruddle; P Strack; M E Dorf; R H DeKruyff
Journal:  J Immunol       Date:  1990-01-01       Impact factor: 5.422

9.  Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles.

Authors:  R M Chicz; R G Urban; J C Gorga; D A Vignali; W S Lane; J L Strominger
Journal:  J Exp Med       Date:  1993-07-01       Impact factor: 14.307

10.  A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E.

Authors:  C Traversari; P van der Bruggen; I F Luescher; C Lurquin; P Chomez; A Van Pel; E De Plaen; A Amar-Costesec; T Boon
Journal:  J Exp Med       Date:  1992-11-01       Impact factor: 14.307

View more
  3 in total

1.  Histological changes in small bowel mucosa induced by gliadin sensitive T lymphocytes can be blocked by anti-interferon gamma antibody.

Authors:  R T Przemioslo; K E Lundin; L M Sollid; J Nelufer; P J Ciclitira
Journal:  Gut       Date:  1995-06       Impact factor: 23.059

2.  Enhanced growth of primary tumors in cancer-prone mice after immunization against the mutant region of an inherited oncoprotein.

Authors:  C T Siegel; K Schreiber; S C Meredith; G B Beck-Engeser; D W Lancki; C A Lazarski; Y X Fu; D A Rowley; H Schreiber
Journal:  J Exp Med       Date:  2000-06-05       Impact factor: 14.307

3.  K-ras mutations and HLA-DR expression in large bowel adenomas.

Authors:  S Norheim Andersen; J Breivik; T Løvig; G I Meling; G Gaudernack; O P Clausen; A Schjölberg; O Fausa; F Langmark; E Lund; T O Rognum
Journal:  Br J Cancer       Date:  1996-07       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.